Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Pozycja w akcjach #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Cena akcji
$0.01292666
Ostatnia synchronizacja: 2025-04-08
Kapitalizacja rynkowa
$157.54K
Zmiana (1 dzień)
6.84%
Zmiana (1 rok)
0.00%
Kraj
GB
Handel Synairgen plc (SNG)

Kategoria

Zyski dla Synairgen plc (SNG)
Zyski w Jun 2024 TTM: $-4.64M
Według najnowszych raportów finansowych Synairgen plc, obecny zysk firmy wynosi $-4.64M. W roku 2022 firma osiągnęła zysk w wysokości $-24.31M, wzrost w porównaniu do zysku z roku 2021, który wynosił $-78.22M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Synairgen plc od 2004 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -113,800.85%
US
$1.95B -42,146.41%
NL
- -
CH
- -
KR
$3.01B -64,888.45%
BE